<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03882749</url>
  </required_header>
  <id_info>
    <org_study_id>CEL-OA-0001</org_study_id>
    <nct_id>NCT03882749</nct_id>
  </id_info>
  <brief_title>Delivra-Celecoxib 8% Cream and Osteoarthritis</brief_title>
  <acronym>Del-Cel</acronym>
  <official_title>A Multicenter Observational Study on the Use of Delivra-Celecoxib 8% Cream on Pain Experienced by Patients With Osteoarthritis of the Knees</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Delivra, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Delivra, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The observation of the clinical use of the Delivra Celecoxib cream (8%) in the treatment of
      osteoarthritis of the knee. Observations will be made over 12 weeks of treatment. Evaluations
      include: pain, functionality and patients global assessment of disease. Patients will self
      administer treatment as prescribed.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 23, 2018</start_date>
  <completion_date type="Anticipated">October 23, 2019</completion_date>
  <primary_completion_date type="Anticipated">July 23, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>11-Point Numerical Rating Scale Pain Index</measure>
    <time_frame>over 12 weeks</time_frame>
    <description>Subjects will rate he pain that they experience from 0-no pain to 10-worst pain inmmaginable</description>
  </primary_outcome>
  <primary_outcome>
    <measure>WOMAC</measure>
    <time_frame>over 12 weeks</time_frame>
    <description>Subjects will describe pain and functionality status using a validated likert assessment .</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse event reporting</measure>
    <time_frame>over 12 weeks</time_frame>
    <description>Subjects will report any adverse events experienced during the study</description>
  </secondary_outcome>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <eligibility>
    <study_pop>
      <textblock>
        This study population is all patients prescribed Del-Cel for the treatment of
        Osteoarthritis of the knees. The treating rheumatologist/ attending clinician will
        determine the appropriate course of treatment for patients as per routine clinical
        practice. Only patients prescribed Del-Cel will be approached for informed consent and
        voluntary participation in this observational study.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Patients with primary osteoarthritis (with radiological evidence) of the knees who
             have been prescribed Del-Cel.

          -  On stable pain therapy with an oral or topical NSAID or acetaminophen.

          -  Able to read and understand English to answer pain assessment questions independently.

          -  Willing and able to fulfill the requirements of the study, including complete
             scheduled follow-up phone visits.

        Exclusion Criteria:

          -  Inability to adequately read and understand English as required to complete study
             assessments and comply with the protocol.

          -  Current recreational or medicinal use of cannabis within 4 weeks of study initiation.

          -  Participants with a lifetime history of cannabis use disorder or other substance use
             disorders (except tobacco use disorder) will be excluded.

          -  Participants with a lifetime history of daily cannabis use will be excluded.

          -  Dose changes of concomitant medication will not be permitted during the study period.

          -  Pregnant women, lactating women, and women of childbearing potential who are not using
             medically accepted forms of contraception (e.g., IUD, oral contraceptives, barrier
             devices, condoms and foam, or implanted progesterone rods stabilized for at least 3
             months), or women who are planning on becoming pregnant.

          -  Diagnosis of any of the following mental disorders as defined by the DSM-5: a lifetime
             history of schizophrenia or any other psychosis, organic medical disorders, bipolar
             disorder. Entry of patients with obsessive compulsive disorder or post- traumatic
             stress disorder will be permitted if the anxiety disorder is judged to be the
             predominant disorder, in order to increase accrual of a clinically relevant sample.

          -  Major depression will be allowed if not severe (Montgomery Åsberg Depression Rating
             Scale-MADRS27≥ 25). Patients with significant suicidal ideation (MADRS item 10 score &gt;
             3) or who have enacted suicidal behaviors within 6 months prior to intake will be
             excluded from study participation and referred for appropriate clinical intervention.

          -  Participants with a family history of schizophrenia spectrum or bipolar disorder will
             be excluded.

          -  Participants who have a history of adverse reactions to cannabis will be excluded.

          -  Known allergy to any of the ingredients in the Delivra base.

          -  Use of Rimonabant (SR141716) within three weeks of enrollment and/or planned use for
             the duration of the study participation[27].

          -  Use of 5-HT1A receptor antagonists (SSRI inhibitors) within three weeks of enrollment
             and/or planned use for the duration of the study participation, e.g.: Pindolol,
             Lecozotan, Brexpiprazole, etc.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Heather Dwyer, MSc</last_name>
    <phone>9055615014</phone>
    <email>hdwyer@delivrainc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dr. Angela Montgomery - Rheumatologist</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5A 3V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quinn Thomson</last_name>
      <phone>(905) 848-2444</phone>
      <email>qthomson@nkshealth.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Brandusa Florica - Rheumatologist</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5A 3V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Quinn Thomson</last_name>
      <phone>(905) 848-2444</phone>
      <email>qthomson@nkshealth.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Andrew Chow - Rheumatologist</name>
      <address>
        <city>Mississauga</city>
        <state>Ontario</state>
        <zip>L5M 2V8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Hum</last_name>
    </contact>
    <contact_backup>
      <phone>905-606-2210</phone>
      <email>cvrheumatology@yahoo.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 18, 2019</study_first_submitted>
  <study_first_submitted_qc>March 18, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 20, 2019</study_first_posted>
  <last_update_submitted>March 18, 2019</last_update_submitted>
  <last_update_submitted_qc>March 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain, WOMAC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

